Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Supplement—December 2022
SUPPLEMENT ISSUE
Clinical

CDC’s COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions

Heidi M. SoetersComments to Author , Reena H. Doshi, Monica Fleming, Oluwasegun Joel Adegoke, Uzoamaka Ajene, Brooke Noel Aksnes, Sarah Bennett, Erin F. Blau, Julie Garon Carlton, Sara Clements, Laura Conklin, Melissa Dahlke, Lindsey M. Duca, Leora R. Feldstein, Jane F. Gidudu, Gavin Grant, Margaret Hercules, Ledor S. Igboh, Atsuyoshi Ishizumi, Sara Jacenko, Yinka Kerr, Nuadum M. Konne, Shibani Kulkarni, Archana Kumar, Kathryn E. Lafond, Eugene Lam, Ashley T. Longley, Margaret McCarron, Apophia Namageyo-Funa, Nancy Ortiz, Jaymin C. Patel, Robert T. Perry, Dimitri Prybylski, Prianca Reddi, Omar Salman, Courtney N. Sciarratta, Talya Shragai, Akshita Siddula, Ester Sikare, Dieula Delissaint Tchoualeu, Denise Traicoff, Alexandra Tuttle, Kerton R. Victory, Aaron Wallace, Kirsten Ward, Man Kai Alyssa Wong, Weigong Zhou, W. William Schluter, David L. Fitter, Anthony Mounts, Joseph S. Bresee, and Terri B. Hyde
Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 1

CDC priority technical areas to support global COVID-19 vaccine implementation through the COVID-19 International Vaccine Implementation and Evaluation (CIVIE) program

Technical area Examples of CDC-supported activities
Vaccine policy development Assist with data review to inform prioritization and planning for vaccination of risk groups
Support and strengthen national-level decision making and National Immunization Technical Advisory Groups via trainings and workshops
Program planning Support microplanning for populations targeted for vaccination
Help design logistical and distribution plans for different vaccination scenarios or products
Vaccine confidence and demand Develop and provide standard tools for country-level adaptation to collect data on behavioral and social barriers to vaccine uptake
Provide support to assess and manage the effect of infodemics* on vaccine confidence and uptake
Provide messaging and communications technical assistance, materials, and tools
Data management and use
 Provide technical assistance to rapidly assess, develop, implement, and monitor data management systems and tools used for COVID-19 vaccine introduction and safety monitoring
Workforce development Conduct rapid performance assessments to understand workforce-related barriers and facilitators to delivering COVID-19 vaccine
Provide evidence-based tools and techniques for improving supervision
Vaccine safety Strengthen passive or enhanced surveillance for adverse events following immunization
Use active surveillance or special studies to address key questions on COVID-19 vaccine safety
Ensure preparedness to respond to safety events through vaccine-related event response planning
Evaluation Support post-introduction evaluations using standard WHO tools
Conduct targeted evaluations of vaccine effectiveness to address key global evidence gaps

*Infodemic, “overabundance of information during a disease outbreak” (17).

Main Article

References
  1. UK Coronavirus Dashboard. Coronavirus (COVID-19) in the UK—vaccinations. 2021 [cited 2021 Sep 2]. https://coronavirus.data.gov.uk/details/vaccinations
  2. Painter  EM, Ussery  EN, Patel  A, Hughes  MM, Zell  ER, Moulia  DL, et al. Demographic characteristics of persons vaccinated during the first month of the COVID-19 vaccination program—United States, December 14, 2020–January 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:174–7. DOIPubMedGoogle Scholar
  3. World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, 8 January 2021. 2021 [cited 2021 Sep 2]. https://apps.who.int/iris/handle/10665/338484
  4. World Health Organization. WHO coronavirus (COVID-19) dashboard. 2022 [cited 2022 Apr 4]. https://covid19.who.int
  5. World Health Organization. Coronavirus disease (COVID-19). WHO—prequalification of medical products. 2022 [cited 2022 Apr 4]. https://extranet.who.int/pqweb/vaccines/covid-19-vaccines
  6. World Health Organization. The Access to COVID-19 Tools (ACT) accelerator. 2020 [cited 2021 Sep 23]. https://www.who.int/initiatives/act-accelerator
  7. World Health Organization. COVAX. 2021 [cited 2021 Oct 12]. https://www.who.int/initiatives/act-accelerator/covax
  8. Gavi. COVAX. 2022 [cited 2022 April 4]. https://www.gavi.org/covax-facility
  9. Berkley  S. COVAX explained. 2020 [cited 2021 Sep 23]. https://www.gavi.org/vaccineswork/covax-explained
  10. US Agency for International Development. USAID’s COVID-19 response. 2021 [cited 2021 Aug 26]. https://www.usaid.gov/coronavirus
  11. The White House. Fact sheet: President Biden’s global COVID-⁠19 summit: ending the pandemic and building back better. 2021 [cited 2021 Sep 23]. https://www.whitehouse.gov/briefing-room/statements-releases/2021/09/22/fact-sheet-president-bidens-global-covid-19-summit-ending-the-pandemic-and-building-back-better
  12. Centers for Disease Control and Prevention. CDC strategy for global response to COVID-19 (2020–2023). 2020 [cited 2021 Sep 23]. https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/global-response-strategy.html
  13. World Health Organization. Immunization agenda 2030. 2021 [cited 2021 Jun 18]. http://www.immunizationagenda2030.org
  14. World Health Organization. Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines: interim guidance. 2021 [cited 2022 Apr 4]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccine-deployment-2021.1-eng
  15. Centers for Disease Control and Prevention. CDC Global Immunization Strategic Framework 2021–2030. 2021 [cited 2022 April 4]. https://www.cdc.gov/globalhealth/immunization/framework/index.html
  16. UNICEF. COVAX information centre. 2021 [cited 2021 Sep 23]. https://www.unicef.org/coronavirus/covax
  17. Centers for Disease Control and Prevention. CDC accelerates global COVID-19 vaccinations through Global Vax. 2022 [cited 2022 Apr 5]. https://www.cdc.gov/coronavirus/2019-ncov/downloads/COVID-19-GLOBAL-VAX-508.pdf
  18. Centers for Disease Control and Prevention. CDC begins third year of COVID-19 response with goal of increasing global vaccination. 2022 [cited 2022 Apr 10]. https://www.cdc.gov/globalhealth/stories/2022/CDC-Begins-Third-Year-COVID19-Response.html
  19. World Health Organization. Infodemic. 2021 [cited 2022 Apr 4]. https://www.who.int/health-topics/infodemic
  20. Williams  SR, Driscoll  AJ, LeBuhn  HM, Chen  WH, Neuzil  KM, Ortiz  JR. National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. Euro Surveill. 2021;26:2001195. DOIPubMedGoogle Scholar
  21. World Health Organization. WHO SAGE roadmap for prioritizing the use of COVID-19 vaccines in the context of limited supply: an approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenarios, 13 November 2020, version 1.1. 2020 [cited 2021 Sep 23]. https://apps.who.int/iris/handle/10665/341448
  22. Tate  J, Aguado  T, Belie  J, Holt  D, Karafillakis  E, Larson  HJ, et al. The life-course approach to vaccination: Harnessing the benefits of vaccination throughout life. Vaccine. 2019;37:6581–3. DOIPubMedGoogle Scholar
  23. Agnandji  ST, Huttner  A, Zinser  ME, Njuguna  P, Dahlke  C, Fernandes  JF, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med. 2016;374:1647–60. DOIPubMedGoogle Scholar
  24. Kennedy  SB, Neaton  JD, Lane  HC, Kieh  MW, Massaquoi  MB, Touchette  NA, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. Clin Trials. 2016;13:49–56. DOIPubMedGoogle Scholar
  25. Henao-Restrepo  AM, Preziosi  M-P, Wood  D, Moorthy  V, Kieny  MP; WHO Ebola Research, Development Team. On a path to accelerate access to Ebola vaccines: The WHO’s research and development efforts during the 2014-2016 Ebola epidemic in West Africa. Curr Opin Virol. 2016;17:138–44. DOIPubMedGoogle Scholar
  26. Henao-Restrepo  AM, Longini  IM, Egger  M, Dean  NE, Edmunds  WJ, Camacho  A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–66. DOIPubMedGoogle Scholar
  27. Aruna  A, Mbala  P, Minikulu  L, Mukadi  D, Bulemfu  D, Edidi  F, et al.; CDC Ebola Response. Ebola Virus Disease Outbreak - Democratic Republic of the Congo, August 2018-November 2019. MMWR Morb Mortal Wkly Rep. 2019;68:1162–5. DOIPubMedGoogle Scholar
  28. Henao-Restrepo  AM, Camacho  A, Longini  IM, Watson  CH, Edmunds  WJ, Egger  M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505–18. DOIPubMedGoogle Scholar
  29. World Health Organization. Ebola virus disease, Democratic Republic of the Congo, external situation report 91. 2020. [cited 2022 Apr 5]. https://apps.who.int/iris/handle/10665/331967
  30. WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, 22–24 March 2021: conclusions and recommendations. Wkly Epidemiol Rec. 2021;96:197–216 https://apps.who.int/iris/bitstream/handle/10665/341623/WER9622-eng-fre.pdf.
  31. Coltart  CE, Johnson  AM, Whitty  CJ. Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Med. 2015;13:271. DOIPubMedGoogle Scholar
  32. Muzembo  BA, Ntontolo  NP, Ngatu  NR, Khatiwada  J, Ngombe  KL, Numbi  OL, et al. Local perspectives on Ebola during its tenth outbreak in DR Congo: A nationwide qualitative study. PLoS One. 2020;15:e0241120. DOIPubMedGoogle Scholar
  33. Dada  S, McKay  G, Mateus  A, Lees  S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R’s). BMC Public Health. 2019;19:1665. DOIPubMedGoogle Scholar
  34. Masumbuko Claude  K, Underschultz  J, Hawkes  MT. Social resistance drives persistent transmission of Ebola virus disease in Eastern Democratic Republic of Congo: A mixed-methods study. PLoS One. 2019;14:e0223104. DOIPubMedGoogle Scholar
  35. Carter  S, Mobula  L, Samaha  H, Ahuka Mundeke  S. Community engagement and vaccinations during the Ebola outbreak in Democratic Republic of Congo. Investing in Health 2020 [cited 2021 Jun 2]. https://blogs.worldbank.org/health/community-engagement-and-vaccinations-during-ebola-outbreak-democratic-republic-congo
  36. Social science and behavioural data compilation (No. 3), Ebola outbreak eastern DRC, February–May 2019. Social Science in Humanitarian Action [cited 2021 Jun 2]. https://opendocs.ids.ac.uk/opendocs/bitstream/handle/20.500.12413/14558/SSHAP_data_compilation_brief_No3_February_May_2019.pdf
  37. Palache  A, Tsai  T, Vasiliev  Y, Abelin  A, Hollingsworth  R, Taylor  B, et al. Global influenza vaccine distribution survey demonstrates urgency of implementation of objective 3 of WHO influenza strategy 2019–2030. Int Med Rev. 2020;6:1–27. DOIGoogle Scholar
  38. Porter  RM, Goldin  S, Lafond  KE, Hedman  L, Ungkuldee  M, Kurzum  J, et al. Does having a seasonal influenza program facilitate pandemic preparedness? An analysis of vaccine deployment during the 2009 pandemic. Vaccine. 2020;38:1152–9. DOIPubMedGoogle Scholar
  39. Ropero-Álvarez  AM, El Omeiri  N, Kurtis  HJ, Danovaro-Holliday  MC, Ruiz-Matus  C. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic. Hum Vaccin Immunother. 2016;12:2206–14. DOIPubMedGoogle Scholar
  40. Bresee  JS, Lafond  KE, McCarron  M, Azziz-Baumgartner  E, Chu  SY, Ebama  M, et al.; PIVI Partners Group. The partnership for influenza vaccine introduction (PIVI): Supporting influenza vaccine program development in low and middle-income countries through public-private partnerships. Vaccine. 2019;37:5089–95. DOIPubMedGoogle Scholar
  41. Bwaka  A, Bita  A, Lingani  C, Fernandez  K, Durupt  A, Mwenda  JM, et al. Status of the rollout of the meningococcal serogroup A conjugate vaccine in African meningitis belt countries in 2018. J Infect Dis. 2019;220(Suppl 4):S140–7. DOIPubMedGoogle Scholar
  42. World Health Organization. Meningococcal meningitis. 2021 [cited 2021 Sep 3]. https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis
  43. Djingarey  MH, Diomandé  FV, Barry  R, Kandolo  D, Shirehwa  F, Lingani  C, et al. Introduction and rollout of a new group A meningococcal conjugate vaccine (PsA-TT) in African meningitis belt countries, 2010–2014. Clin Infect Dis. 2015;61(Suppl 5):S434–41. DOIPubMedGoogle Scholar
  44. Trotter  CL, Lingani  C, Fernandez  K, Cooper  LV, Bita  A, Tevi-Benissan  C, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. Lancet Infect Dis. 2017;17:867–72. DOIPubMedGoogle Scholar
  45. Nusair  MB, Arabyat  R, Khasawneh  R, Al-Azzam  S, Nusir  AT, Alhayek  MY. Assessment of the relationship between COVID-19 risk perception and vaccine acceptance: a cross-sectional study in Jordan. Hum Vaccin Immunother. 2022;18:2017734. DOIPubMedGoogle Scholar
  46. Meningococcal A conjugate vaccine: updated guidance, February 2015. Wkly Epidemiol Rec. 2015;90:57–62.PubMedGoogle Scholar
  47. World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2020 global summary. 2020 [cited 2022 Apr 4]. https://apps.who.int/immunization_monitoring/globalsummary/schedules

Main Article

Page created: May 27, 2022
Page updated: December 11, 2022
Page reviewed: December 11, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external